In women with treatments, HER2+ (adjusted HR 2.18; 95% CI 1.46 to 3.28; P = 0.0001) and TNBC (1.5; 95% CI 1.11 to 2.04; P = 0.0091) subtypes were significantly associated with the decreased survival by multivariable analysis adjusting for age, tumor size and grade, number of positive nodes, stage and breast cancer subtypes (Table 3). The gene discussed is ERBB2; the disease is breast carcinoma.